Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CTSV | O60911 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30061165 | 1.00 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL7552860 | 0.97 | MEN1 (0.53) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL27581338 | 0.94 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL5344847 | 0.92 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL12734031 | 0.92 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL1300529 | 0.91 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL7907625 | 0.90 | MEN1 (0.54) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL7152494 | 0.89 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL564301 | 0.89 | POLB (0.48) | MEN1KMT2ANPC1RAB9AATM | |
| SCHEMBL564577 | 0.89 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1207269-C | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof | UNIV SHANGHAI JIAOTONG (CN) | 2005-06-22 | — | — | CN | claimed |
| CN-1472191-A | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof | 上海交通大学 | 2004-02-04 | — | — | CN | claimed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026481-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4125874-A1 | LIPOXYGENASE INHIBITORS | SRI International (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335046-A | Lipoxygenase inhibitors | 思研（SRI）国际顾问与咨询公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021195346-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021195346-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2019141980-A1 | AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141980-A1 | AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2019-07-25 | — | — | WO | disclosed |
| EP-1963294-B1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8119666-B2 | 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1963294-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067613-A1 | 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| CN-1207269-C | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof | UNIV SHANGHAI JIAOTONG (CN) | 2005-06-22 | — | — | CN | disclosed |
| CN-1472191-A | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof | 上海交通大学 | 2004-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293776-A1 | 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) | PTPRS, PTPN5, PTPRR | MEN1 3927/4885KMT2A 2549/4885NPC1 3005/4885 |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | MEN1 4167/4885KMT2A 2425/4885NPC1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.